VentriPoint Diagnostics Ltd (V:VPT) — Market Cap & Net Worth
Market Cap & Net Worth: VentriPoint Diagnostics Ltd (VPT)
VentriPoint Diagnostics Ltd (V:VPT) has a market capitalization of $14.93 Million (CA$20.64 Million) as of July 22, 2026. Listed on the V stock exchange, this Canada-based company holds position #26026 globally and #1037 in its home market, demonstrating a 7.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VentriPoint Diagnostics Ltd's stock price CA$0.11 by its total outstanding shares 187659191 (187.66 Million). Review how much free cash does VentriPoint Diagnostics Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
VentriPoint Diagnostics Ltd Market Cap History: 2015 to 2026
VentriPoint Diagnostics Ltd's market capitalization history from 2015 to 2026. Data shows change from $38.01 Million to $14.93 Million (-11.31% CAGR).
VentriPoint Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VentriPoint Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
142.64x
VentriPoint Diagnostics Ltd's market cap is 142.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $38.01 Million | $55.78K | -$1.51 Million | 681.39x | N/A |
| 2016 | $16.29 Million | $209.48K | -$2.62 Million | 77.76x | N/A |
| 2017 | $42.08 Million | $38.91K | -$3.70 Million | 1081.67x | N/A |
| 2018 | $21.04 Million | $60.18K | -$2.08 Million | 349.66x | N/A |
| 2019 | $10.86 Million | $81.02K | -$3.32 Million | 134.04x | N/A |
| 2020 | $12.22 Million | $36.02K | -$1.85 Million | 339.21x | N/A |
| 2022 | $36.65 Million | $68.17K | -$4.87 Million | 537.69x | N/A |
| 2023 | $40.72 Million | $49.18K | -$4.87 Million | 828.03x | N/A |
| 2024 | $13.57 Million | $95.17K | -$4.92 Million | 142.64x | N/A |
Competitor Companies of VPT by Market Capitalization
Companies near VentriPoint Diagnostics Ltd in the global market cap rankings as of July 22, 2026.
Key companies related to VentriPoint Diagnostics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $176.77 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #196 globally with a market cap of $122.13 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #235 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #240 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $176.77 Billion | $101.66 |
| #196 | Stryker Corporation | NYSE:SYK | $122.13 Billion | $319.14 |
| #235 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #240 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $83.29 |
VentriPoint Diagnostics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, VentriPoint Diagnostics Ltd's market cap moved from $38.01 Million to $ 14.93 Million, with a yearly change of -11.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$14.93 Million | -21.43% |
| 2025 | CA$19.00 Million | +40.00% |
| 2024 | CA$13.57 Million | -66.67% |
| 2023 | CA$40.72 Million | +11.11% |
| 2022 | CA$36.65 Million | -21.74% |
| 2021 | CA$46.83 Million | +283.33% |
| 2020 | CA$12.22 Million | +12.50% |
| 2019 | CA$10.86 Million | -48.39% |
| 2018 | CA$21.04 Million | -50.00% |
| 2017 | CA$42.08 Million | +158.33% |
| 2016 | CA$16.29 Million | -57.14% |
| 2015 | CA$38.01 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of VentriPoint Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.93 Million USD |
| MoneyControl | $14.93 Million USD |
| MarketWatch | $14.93 Million USD |
| marketcap.company | $14.93 Million USD |
| Reuters | $14.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VentriPoint Diagnostics Ltd
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. It also provid… Read more